FDA Expands Pediatric Indication for Rozlytrek (entrectinib) and Approves New Pellet Formulation

On October 20, 2023, the Food and Drug Administration granted accelerated approval to entrectinib (Rozlytrek, Genentech Inc.) for pediatric patients older than 1 month with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news